This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

HIV Researchers Celebrate 20 Years Of Collaboration

Stocks in this article: CERN

KANSAS CITY, Mo., April 23, 2013 (GLOBE NEWSWIRE) -- The HIV Outpatient Study (HOPS), supported by Cerner's Infectious Disease Insights group, HIV clinic researchers, and the dedicated project team from the Centers for Disease Control and Prevention (CDC) will be celebrating its 20th Anniversary during the Annual HOPS Investigator meeting held in April in Tampa, Fla.

HOPS, one of the largest U.S. government-funded longitudinal cohort studies, follows HIV-infected patients to gain insights to improve prevention and treatment of HIV/AIDS. CDC initiated the study in 1993 to describe and monitor trends in demographics, symptoms, diagnoses, and treatments in a population of HIV-infected outpatients in nine clinics across the United States. HOPS researchers at these clinics gather clinical, immunologic and virologic data, as well as genotypic and phenotypic information through periodic reviews of medical records.

Through analysis of HOPS data, researchers have verified the impact of existing therapeutics, gained knowledge to inform new best practices in prevention and treatment and discovered new concerns warranting additional study. To date, researchers have shared HOPS study findings through 56 published manuscripts and 115 abstracts and presentations, thus enhancing the medical community's understanding of prolonged survival, the metabolic problems associated with combination antiretroviral therapy (cART), adherence to cART, and the occurrence of comorbidities.

"HOPS is a unique study that highlights the power of true collaboration," said Dr. Sam Bozzette, a Cerner executive and internationally-recognized HIV researcher who provides strategic oversight to Cerner's HOPS team. "HOPS is designed to encourage the exchange of ideas among the research stakeholders from the CDC and participating clinic sites and provides them with the flexibility and agility to explore concerns and ideas as they become apparent."

Dr. John T. Brooks, the medical epidemiologist in CDC's Division of HIV/AIDS Prevention who oversees the study, commented, "HOPS has been instrumental in highlighting the health challenges faced by persons living with HIV in the United States. He added, "Through analyses of data from more than 9,000 HIV-infected patients who volunteered to participate in this research from 1993 to date, we have been able to document new complications associated with chronic HIV disease such as cardiovascular and bone disorders. We also continue to demonstrate the value of cART and preventative strategies for extending and improving patients' lives."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs